BioGeometry, in collaboration with Jianwei Zhu’s team from Shanghai Jiao Tong University’s School of Pharmacy, achieved a remarkable increase in the neutralizing activity of the 8G3 antibody against the latest JN.1 virus variant, boosting it by 1000-1500 times in a short period.
BioGeometry’s generative AI model, GeoFlow, redesigns the hydrophobic regions of transmembrane proteins to be soluble in water while retaining their structure and function.
BioGeometry was honored with the “Computing Power Star” award for its breakthrough in denovo protein design using generative AI and geometric deep learning.
This strategic partnership will leverage the strengths of both companies to advance innovative vaccine development and production, creating cutting-edge vaccines in China and contributing to global health.
Building on the success of previous projects, the two parties aim to jointly explore high-value market opportunities.
Driving the transformation towards a digital, intelligent and sustainable future
Learn MoreBioGeometry secures Pre-A round funding to advance GenAI for biosolutions
Antibody-antigen docking performance on par with AlphaFold3
Learn MoreIntroducing GeoFlow: Next-Gen Generative Model for Antibody Modeling and Design
Both parties will create a next-generation AIGC-driven antibody drug discovery platform jointly and promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.
Both parties will fully leverage their respective strengths in a comprehensive strategic collaboration within the field of large molecule pharmaceuticals, aiming to achieve breakthrough progress in antibody drug R&D through the application of AI technology.
The two parties will engage in deep collaboration on platform products, project optimization services, and resource expansion to promote innovation together in antibody research and development, providing pharmaceutical clients with higher-quality R&D services.
Learn MoreBioGeometry and BioMetas Join Hands to Empower Development of Novel Large Molecule Drugs
中文